Eli Lilly to Acquire AtaiBeckley for up to $3.8B, Betting Big on Psychedelic Medicine
The pharma giant is buying the clinical-stage biotech behind BPL-003 — a synthetic 5-MeO-DMT for treatment-resistant depression — in a deal that pushes psychedelic therapy firmly into the mainstream drug industry.
Editorial Team · 1 min read
Anthropic Launches "Claude Science," an AI Workbench Aimed at Biology and Drug Discovery
The company behind Claude has released a research environment that pulls genomics, proteomics, and cheminformatics tools into one place — and is offering academic labs up to $30,000 in credits to try it.
Editorial Team · 4 min read
Anodyne Nanotech Raises $12.6M Series A to Take a Once-Weekly GLP-1 Patch into Human Trials
The Boston biotech wants to replace the GLP-1 injection with a room-temperature patch — no needles, no cold storage. Its Series A funds the first clinical test of that idea.
Editorial Team · 3 min read
Insilico Medicine Signs AI Drug-Discovery Deal With SK Biopharmaceuticals Worth Up to $2.5 Billion
The AI-driven biotech will run target-to-candidate discovery for neuroimmune disorders, while its Korean partner takes the molecules through late-stage development - Insilico's largest potential deal in Asia-Pacific to date.
Editorial Team · 4 min read
Life Biosciences Doses First Patient in Landmark Trial of Cellular-Reprogramming Therapy for Vision Loss
ER-100 is one of the first attempts to take partial epigenetic reprogramming — resetting cells to a "younger" state — from the lab into a human trial. The first patient has now been dosed.
Editorial Team · 4 min read